You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

31 search results for: disease control

Current Treatment Options are not Effective for Achieving Full <b>Disease</b> <b>Control</b> in All Patients with CSU

expert video

Current Treatment Options are not Effective for Achieving Full Disease Control in All Patients with CSU

1 min

Dermatology

Dr. Casale presents the data on the use of antihistamines at licensed doses, indicating that only a minority achieve disease control.

The Impact of Advanced Systemic Therapies on <b>Disease</b> <b>Control</b> and Potential Remission in Atopic Dermatitis

expert video

The Impact of Advanced Systemic Therapies on Disease Control and Potential Remission in Atopic Dermatitis

10 min

Dermatology

Exploring the concept of disease modification relating to therapeutic interventions with targeted systemic therapies in atopic dermatitis.

Impact of Advanced Systemic Therapies on <b>Disease</b> <b>Control</b> in AD

expert video

Impact of Advanced Systemic Therapies on Disease Control in AD

6 min

Dermatology

Dr. Simpson discusses impact of advanced systemic therapies in AD, and the link between inhibition of type 2 inflammation and reduced IgE levels.

Describing <b>Disease</b> <b>Control</b> in PN

expert video

Describing Disease Control in PN

5 min

Dermatology

Dr. Chovatiya discusses PN, emphasizing that while itch is a major symptom, the disease's burden is multi-dimensional, affecting appearance, sleep, social life, and mental health, requiring comprehensive therapeutic solutions.

expert video

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission

8 min

Pulmonology

Watch Prof G. Walter Canonica discuss the need to move beyond disease control to clinical remission in asthma and CRSwNP.

What do we mean by <b>disease</b> <b>control</b> in AD?

expert video

What do we mean by disease control in AD?

3 min

Dermatology

Dr. Eric Simpson discusses the differing goals of patients and physicians in treating atopic dermatitis and emphasizes the importance of patient input.

Comparative Efficacy of Biologics for Patients with Un<b>control</b>led and/or Severe CRSwNP

expert video

Comparative Efficacy of Biologics for Patients with Uncontrolled and/or Severe CRSwNP

7 min

Rhinology

Prof. Peter Hellings presents the comparative efficacy of biologics for patients with uncontrolled and/or severe CRSwNP.

From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Un<b>control</b>led and/or Severe CRSwNP

expert video

From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

9 min

Rhinology

Prof. Peter Hellings discusses the interconnection between the pathophysiology, burden and clinical management of uncontrolled and/or severe CRSwNP.

New Perspectives on <b>Disease</b> Modification in Atopic Dermatitis

expert video

New Perspectives on Disease Modification in Atopic Dermatitis

48 min

Dermatology

An exploration into the concept and potential of disease modification through therapeutic interventions in AD.

Exploring The Concept of <b>Disease</b> Modification in Atopic Dermatitis

expert video

Exploring The Concept of Disease Modification in Atopic Dermatitis

13 min

Dermatology

Exploring the concept of disease modification and related pathomechanisms in atopic dermatitis.

New Perspectives on <b>Disease</b> Modification in Atopic Dermatitis - Panel Discussion

expert video

New Perspectives on Disease Modification in Atopic Dermatitis - Panel Discussion

10 min

Dermatology

Panel discussion exploring what disease modification could involve in atopic dermatitis.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: GreeceChange country/region